AKUS · Akouos, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | - | - |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $64.59M | $34.30M |
| SG&A | $22.23M | $14.58M |
| Total Operating Expenses | $86.82M | $48.88M |
| D&A | $2.49M | $1.93M |
| Operating Income | ($86.82M) | ($48.88M) |
| Interest Expense | - | - |
| Income Tax | $0 | $0 |
| Net Income | ($86.67M) | ($48.60M) |
| EPS - Basic | ($2.77) | - |
| EPS - Diluted | ($2.77) | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Cash & Equivalents | $121.91M | $68.93M |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $1.28M | $895.0K |
| Current Assets | $236.16M | $310.64M |
| Total Assets | $278.75M | $333.35M |
| Current Liabilities | $16.80M | $10.71M |
| Long-term Debt | - | - |
| Total Liabilities | $45.10M | $22.74M |
| Stockholders' Equity | $233.65M | $310.61M |
| Retained Earnings | ($168.40M) | ($81.72M) |
Cash Flow
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Operating Cash Flow | ($63.73M) | ($40.77M) |
| Investing Cash Flow | $117.62M | ($243.88M) |
| Financing Cash Flow | $217.0K | $328.50M |
| CapEx | $9.02M | $4.53M |
| Free Cash Flow | ($72.75M) | ($45.30M) |
Ratios
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | - |
| EBITDA margin | - | - |
| Net margin | - | - |
| Free cash flow margin | - | - |
| FCF / Net income | 0.84 | 0.93 |
| R&D / Revenue | - | - |
| SG&A / Revenue | - | - |
| Effective tax rate | - | - |
| Return on assets | -31.1% | -14.6% |
| Return on equity | -37.1% | -15.6% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 14.06 | 29.01 |
| Quick ratio | 14.06 | 29.01 |
| Cash ratio | 7.26 | 6.44 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | 1.19 | 1.07 |
| Liabilities / Assets | 0.16 | 0.07 |
| Efficiency | ||
| Asset turnover | - | - |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -77.6% | - |
| Net income growth (YoY) | -78.3% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -60.6% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -24.8% | - |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Akouos against the 5 most active filers in the same SIC group.